Onkológia 5/2014
Treatment of relapse and refractory chronic lymphocytic leukemia
Despite the widespread use of highly effective chemoimmunotherapy, refractory chronic lymphocytic leukemia remains a challenging clinical problem associated with poor overall survival. Approved therapeutic options of refractory chronic lymphocytic leukemia for these patients remain limited, and the goal of therapy for physically fit patients is to achieve adequate cytoreduction to proceed to allogeneic stem cell transplantation. Fortunately, several novel targeted therapeutics in clinical trials hold promise of significant benefit for this patient population.
Keywords: chronic lymphocytic leukemia, relapse, refractory disease, remission.
